PHARMACYTE BIOTECH, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PHARMACYTE BIOTECH, INC. (PMCB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $236.06 thousand for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-29.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-09-14
- PHARMACYTE BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-01-31 was $60.49K, a 16.98% decline year-over-year.
- PHARMACYTE BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-10-31 was $60.49K, a 49.23% decline year-over-year.
- PHARMACYTE BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-07-31 was $60.49K, a 72.83% decline year-over-year.
- PHARMACYTE BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-01-31 was $72.86K, a 89.20% decline year-over-year.
- PHARMACYTE BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2026 was $236.06K, a 50.68% decline from fiscal 2025.
- PHARMACYTE BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $478.64K, a 29.06% decline from fiscal 2024.
- PHARMACYTE BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $674.69K, a 5.74% increase from fiscal 2023.
- PHARMACYTE BIOTECH, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $638.07K, a 1323.95% increase from fiscal 2022.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-04-30 | $236.06K 10-K · filed 2026-07-29 | |||
| 2026-01-31 | $60.49K 10-Q · filed 2026-03-17 | $120.98K derived: sum of 2 quarters · filed 2026-03-17 | $181.48K derived: sum of 3 quarters · filed 2026-09-14 | |
| 2025-10-31 | $60.49K 10-Q · filed 2026-03-17 | $120.98K derived: sum of 2 quarters · filed 2026-09-14 | ||
| 2025-07-31 | $60.49K 10-Q · filed 2026-09-14 | |||
| 2025-04-30 | $478.64K 10-K · filed 2026-07-29 | |||
| 2025-01-31 | $72.86K 10-Q · filed 2026-03-17 | $192.02K derived: sum of 2 quarters · filed 2026-03-17 | $414.69K derived: sum of 3 quarters · filed 2026-03-17 | |
| 2024-10-31 | $119.16K 10-Q · filed 2026-03-17 | $341.83K derived: sum of 2 quarters · filed 2026-03-17 | ||
| 2024-07-31 | $222.68K 10-Q · filed 2026-03-17 | |||
| 2024-04-30 | $674.69K 10-K · filed 2025-08-11 | |||
| 2024-01-31 | $674.69K 10-Q · filed 2025-03-17 | |||
| 2023-04-30 | $638.07K 10-K · filed 2024-08-13 | |||
| 2023-01-31 | $629.26K 10-Q · filed 2023-03-16 | $633.48K derived: sum of 2 quarters · filed 2023-03-16 | $638.07K derived: sum of 3 quarters · filed 2024-03-18 | |
| 2022-10-31 | $4.21K 10-Q · filed 2023-03-16 | $8.81K derived: sum of 2 quarters · filed 2024-03-18 | ||
| 2022-07-31 | $4.59K 10-Q · filed 2024-03-18 | |||
| 2022-04-30 | $44.81K 10-K · filed 2023-07-31 | |||
| 2022-01-31 | $7.37K 10-Q · filed 2023-03-16 | $17.75K derived: sum of 2 quarters · filed 2023-03-16 | $41.89K derived: sum of 3 quarters · filed 2023-03-16 | |
| 2021-10-31 | $10.38K 10-Q · filed 2023-03-16 | $34.53K derived: sum of 2 quarters · filed 2023-03-16 | ||
| 2021-07-31 | $24.14K 10-Q · filed 2023-03-16 | |||
| 2021-04-30 | $176.57K 10-K · filed 2022-07-28 | |||
| 2021-01-31 | $38.61K 10-Q · filed 2022-03-15 | $94.67K derived: sum of 2 quarters · filed 2022-03-15 | $166.98K derived: sum of 3 quarters · filed 2022-03-15 | |
| 2020-10-31 | $56.06K 10-Q · filed 2022-03-15 | $128.38K derived: sum of 2 quarters · filed 2022-03-15 | ||
| 2020-07-31 | $72.32K 10-Q · filed 2022-03-15 | |||
| 2020-04-30 | $379.38K 10-K · filed 2021-08-10 | |||
| 2020-01-31 | $84.44K 10-Q · filed 2020-03-13 | $182.84K derived: sum of 2 quarters · filed 2020-03-13 | $309.17K derived: sum of 3 quarters · filed 2020-09-11 | |
| 2019-10-31 | $98.41K 10-Q · filed 2020-03-13 | $224.73K derived: sum of 2 quarters · filed 2020-09-11 | ||
| 2019-07-31 | $126.33K 10-Q · filed 2020-09-11 | |||
| 2019-04-30 | $412.35K 10-K · filed 2020-08-13 | |||
| 2019-01-31 | $72.48K 10-Q · filed 2020-03-13 | $169.45K derived: sum of 2 quarters · filed 2020-03-13 | $282.67K derived: sum of 3 quarters · filed 2020-03-13 | |
| 2018-10-31 | $96.96K 10-Q · filed 2020-03-13 | $210.19K derived: sum of 2 quarters · filed 2020-03-13 | ||
| 2018-07-31 | $113.22K 10-Q · filed 2020-03-13 | |||
| 2018-04-30 | $945.08K 10-K · filed 2019-08-13 | |||
| 2018-01-31 | $306.91K 10-Q · filed 2019-03-14 | $552.00K derived: sum of 2 quarters · filed 2019-03-14 | $796.70K derived: sum of 3 quarters · filed 2019-03-14 | |
| 2017-10-31 | $245.09K 10-Q · filed 2019-03-14 | $489.80K derived: sum of 2 quarters · filed 2019-03-14 | ||
| 2017-07-31 | $244.70K 10-Q · filed 2019-03-14 | |||
| 2017-04-30 | $597.40K 10-K · filed 2018-07-20 | |||
| 2016-04-30 | $788.77K 10-K · filed 2017-07-27 | |||
| 2015-04-30 | $5.24M 10-K · filed 2016-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |